ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Microbiome-targeting treatment is set to evolve, address multiple immunological indications: GlobalData
July 12, 2021Microbiome is a space with high potential, a fact underlined by the complete absence of microbiome-targeting treatments on the market. -
Final NHS green light for Allergan’s IBS-D drug
September 01, 2017Allergan’s Truberzi has become the first treatment for irritable bowel syndrome with diarrhoea (IBS-D) to be reviewed and recommended by the National Institute for Health and Care Excellence for use on the NHS in England and Wales. -
NICE nod for Allergan’s Truberzi for IBS-D
July 31, 2017Cost regulators for NHS treatments in England and Wales are backing use of Allergan’s Truberzi to treat irritable bowel syndrome with diarrhoea (IBS-D) in patients who have not responded to or cannot take other treatments.-D -
New data reinforce the effectiveness of Viberzi to treat the symptoms associated with IBS-D
July 13, 2017Viberzi proven safe and effective in patients who reported inadequate response to prior loperamide use.
Pharma Sources Insight January 2025
